The Danish drugmaker's new 3 mg formulation, which, when approved, will be marketed as Saxenda, has been given a positive opinion as an adjunct to a reduced-calorie diet and increased physical ...

The EMA has given a green light to Novo Nordisk's obesity drug Saxenda, adding to earlier approvals in the US and Canada. The 3mg formulation of liraglutide has been approved by the EU regulator ...